News | February 08, 2009

Modified Angioplasty Procedure May Reduce Heart Damage

February 9, 2009 - Emory University cardiologists are testing a modification of angioplasty known as postconditioning, designed to reduce permanent damage to the heart muscle after a heart attack.

The rush of blood back into the heart after a blood vessel is reopened during angioplasty can produce “reperfusion injury,” caused by biochemical changes in the heart muscle. The modified procedure inflates and deflates the balloon several times in a precisely controlled way, so that blood back flows into the heart gradually and thereby reduces the risk of reperfusion injury.

"This study could help refine a common, well-established procedure performed on thousands of patients every year," said principal investigator Habib Samady, M.D., associate professor of medicine (cardiology) at Emory University School of Medicine. "Without involving any additional drugs or devices, it may be possible to reduce damage to the heart muscle in a very straightforward way."

The Emory study — one of the first to test postconditioning in the U.S. — aims to determine whether postconditioning can benefit patients undergoing angioplasty and if so, to define how.

Post-conditioning has been tested in France, Israel, Denmark and Canada. In addition, a 2007 retrospective study of heart attack patients in Massachusetts who, without prior planning by doctors, required several balloon inflations showed that these patients had less damage to their hearts.

The Emory investigators will assess the degree of heart muscle damage in groups of patients treated with standard angioplasty versus those treated with a modified procedure using MRI and echocardiography.

The Emory study began in September 2008 and doctors have already treated several patients with the modified angioplasty procedure, with a total of 40 participants planned.

For more information: www.whsc.emory.edu

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init